N-(4-iodophenyl)-4-pyridinecarboxamide | 302806-41-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-iodophenyl)-4-pyridinecarboxamide
• 英文别名: N-(4-iodophenyl)pyridine-4-carboxamide
• CAS: 302806-41-3
• 化学式: C₁₂H₉IN₂O
• mdl: MFCD00805693
• 分子量: 324.121
• InChiKey: ATYCENZUNOKOMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4-iodophenyl)-4-pyridinecarboxamide 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三异丙基-胺 、 甲基磺酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 2,2',2''-(10-((4-((4-(isonicotinamido)phenyl)-ethynyl) pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-acetic acid
  参考文献：
  名称：

  Real-time in situ monitoring via europium emission of the photo-release of antitumor cisplatin from a Eu–Pt complex

  摘要：

  一种光响应型抗肿瘤药物PtEuL已经合成并通过线性/双光子激发在体外评估用于控制顺铂释放，同时伴随着Eu发射的开启作为响应性可追踪信号。

  DOI：

  10.1039/c5cc05461c
• 作为产物：
  描述：

  异烟酸 、 对碘苯胺 在 4-二甲氨基吡啶 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以89%的产率得到N-(4-iodophenyl)-4-pyridinecarboxamide
  参考文献：
  名称：

  Real-time in situ monitoring via europium emission of the photo-release of antitumor cisplatin from a Eu–Pt complex

  摘要：

  一种光响应型抗肿瘤药物PtEuL已经合成并通过线性/双光子激发在体外评估用于控制顺铂释放，同时伴随着Eu发射的开启作为响应性可追踪信号。

  DOI：

  10.1039/c5cc05461c

文献信息

• Rhodium(iii)-catalyzed oxidative mono- and di-olefination of isonicotinamides
  作者：Xiaohong Wei、Feng Wang、Guoyong Song、Zhengyin Du、Xingwei Li

  DOI：10.1039/c2ob25773d

  日期：——

  [RhCp*Cl2]2 can catalyze the oxidative coupling of secondary isonicotinamides with activated olefins using Cu(OAc)2 as an oxidant. The selectivity can be controlled by the solvent. In MeCN, the mono-olefination and two-fold oxidation reaction is the major pathway, while in THF this reaction gave mostly diolefination products. In both cases, the coupled products contain an exocyclic CC bond.

  [RhCp*Cl2]2能催化次异烟酰胺与活泼烯烃的氧化偶联反应，以Cu(OAc)2作为氧化剂。通过溶剂可以选择性地控制反应。在乙腈中，单烯化与双氧化反应是主要途径，而在四氢呋喃中该反应主要得到二烯化产物。两种情况下，偶联产物都含有一个环外碳碳键。
• Amide inhibitors of microsomal triglyceride transfer protein
  申请人：——

  公开号：US20020156281A1

  公开（公告）日：2002-10-24

  The present invention provides compounds having the Formula I 1 The present invention also provides pharmaceutical compositions comprising a compound of Formula I and methods of treatment of atherosclerosis, obesity, restenosis, coronary heart disease, hyperlipoproteinemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明提供具有化学式I的化合物。本发明还提供包含化合物I的药物组合物，以及治疗动脉粥样硬化、肥胖症、再狭窄、冠心病、高脂蛋白血症、高胆固醇血症和高甘油三酯血症的方法。
• lanthanide toolbox for multi-modal, non-invasive tumor specific theranostic prodrugs
  申请人：Hong Kong Baptist University

  公开号：US20180078564A1

  公开（公告）日：2018-03-22

  The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin αvβ3.

  本公开涉及具有体外或体内响应信号的治疗诊断前药及其用途。它还涉及合成的铕配合物，用于评估与整合素αvβ3的结合。
• Lanthanide toolbox for multi-modal, non-invasive tumor specific theranostic prodrugs
  申请人：Hong Kong Baptist University

  公开号：US10183027B2

  公开（公告）日：2019-01-22

  The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin αvβ3.

  本公开涉及具有体外或体内响应信号的治疗原药及其用途。它还涉及用于评估与整合素 αvβ3 结合情况的合成铕复合物。
• Pyridinium cationic-dimer antimalarials, unlike chloroquine, act selectively between the schizont stage and the ring stage of Plasmodium falciparum
  作者：Mai Yoshikawa、Kazunori Motoshima、Kanji Fujimoto、Akihiro Tai、Hiroki Kakuta、Kenji Sasaki

  DOI：10.1016/j.bmc.2008.04.051

  日期：2008.6

  Malaria is a leading cause of death in developing countries, and the emergence of strains resistant to the main therapeutic agent, chloroquine, has become a serious problem. We have developed cationic-dimer type antimalarials, MAP-610 and PMAP-H10, which are structurally different from chloroquine. In this study, we introduced several substituents on the terminal phenyl rings of PMAP-H10. The electronic and hydrophobic properties of the substituents were correlated with the antimalarial activity and cytotoxicity of the compounds, respectively. Studies with synchronized cultures of malarial plasmodia showed that our cationic-dimers act selectively between the schizont stage and the ring stage of the parasitic cycle, unlike chloroquine, which has a stage-independent action. Thus, the mechanism of action of our antimalarials appears to be different from that of chloroquine, and our compounds may be effective against chloroquine-resistant strains. (C) 2008 Published by Elsevier Ltd.